In conclusion, using bioinformatic analysis we established a rationale for identifying critical pathways as well as substitute genes and Core Signature genes that would facilitate clinical application of HTICS and may uncover new therapeutic targets for HER2+:ERα- breast cancer. Here, ERBB2 is linked to breast carcinoma.